Vertex Pharmaceuticals Incorporated (VRTX)
USD 501.15
(0.46%)
USD 501.15
(0.46%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 22.73 Billion USD | 25.23% |
| 2022 | 18.15 Billion USD | 35.13% |
| 2021 | 13.43 Billion USD | 14.3% |
| 2020 | 11.75 Billion USD | 41.27% |
| 2019 | 8.31 Billion USD | 33.18% |
| 2018 | 6.24 Billion USD | 76.14% |
| 2017 | 3.54 Billion USD | 22.54% |
| 2016 | 2.89 Billion USD | 15.89% |
| 2015 | 2.49 Billion USD | 6.88% |
| 2014 | 2.33 Billion USD | 0.74% |
| 2013 | 2.31 Billion USD | -15.96% |
| 2012 | 2.75 Billion USD | 25.18% |
| 2011 | 2.2 Billion USD | 27.75% |
| 2010 | 1.72 Billion USD | -11.76% |
| 2009 | 1.95 Billion USD | 99.44% |
| 2008 | 980.47 Million USD | 63.01% |
| 2007 | 601.47 Million USD | -34.73% |
| 2006 | 921.57 Million USD | 67.87% |
| 2005 | 548.99 Million USD | 0.65% |
| 2004 | 545.45 Million USD | -24.7% |
| 2003 | 724.41 Million USD | -11.19% |
| 2002 | 815.72 Million USD | -11.83% |
| 2001 | 925.13 Million USD | 19.7% |
| 2000 | 772.88 Million USD | 232.56% |
| 1999 | 232.4 Million USD | -12.73% |
| 1998 | 266.3 Million USD | -9.91% |
| 1997 | 295.6 Million USD | 105.99% |
| 1996 | 143.5 Million USD | 44.95% |
| 1995 | 99 Million USD | -14.8% |
| 1994 | 116.2 Million USD | 90.49% |
| 1993 | 61 Million USD | 19.61% |
| 1992 | 51 Million USD | -10.68% |
| 1991 | 57.1 Million USD | 520.65% |
| 1990 | 9.2 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 23.91 Billion USD | 5.22% |
| 2024 Q3 | 22.24 Billion USD | 10.47% |
| 2024 Q2 | 20.13 Billion USD | -15.83% |
| 2023 FY | 22.73 Billion USD | 25.23% |
| 2023 Q1 | 18.97 Billion USD | 4.54% |
| 2023 Q3 | 21.72 Billion USD | 6.77% |
| 2023 Q4 | 22.73 Billion USD | 4.62% |
| 2023 Q2 | 20.34 Billion USD | 7.25% |
| 2022 FY | 18.15 Billion USD | 35.13% |
| 2022 Q4 | 18.15 Billion USD | 8.65% |
| 2022 Q3 | 16.7 Billion USD | 7.21% |
| 2022 Q2 | 15.58 Billion USD | 9.3% |
| 2022 Q1 | 14.25 Billion USD | 6.13% |
| 2021 Q1 | 12.11 Billion USD | 3.09% |
| 2021 Q2 | 12.22 Billion USD | 0.88% |
| 2021 Q3 | 12.61 Billion USD | 3.25% |
| 2021 Q4 | 13.43 Billion USD | 6.45% |
| 2021 FY | 13.43 Billion USD | 14.3% |
| 2020 Q2 | 10.21 Billion USD | 14.88% |
| 2020 Q4 | 11.75 Billion USD | 3.98% |
| 2020 Q1 | 8.89 Billion USD | 6.91% |
| 2020 FY | 11.75 Billion USD | 41.27% |
| 2020 Q3 | 11.3 Billion USD | 10.62% |
| 2019 Q3 | 7.51 Billion USD | 6.84% |
| 2019 Q2 | 7.03 Billion USD | 7.49% |
| 2019 Q1 | 6.54 Billion USD | 4.76% |
| 2019 Q4 | 8.31 Billion USD | 10.7% |
| 2019 FY | 8.31 Billion USD | 33.18% |
| 2018 FY | 6.24 Billion USD | 76.14% |
| 2018 Q4 | 6.24 Billion USD | 35.17% |
| 2018 Q3 | 4.62 Billion USD | 6.58% |
| 2018 Q2 | 4.33 Billion USD | 9.67% |
| 2018 Q1 | 3.95 Billion USD | 11.48% |
| 2017 Q2 | 3.28 Billion USD | 11.5% |
| 2017 Q3 | 3.19 Billion USD | -2.66% |
| 2017 Q4 | 3.54 Billion USD | 10.87% |
| 2017 FY | 3.54 Billion USD | 22.54% |
| 2017 Q1 | 2.94 Billion USD | 1.83% |
| 2016 Q1 | 2.48 Billion USD | -0.37% |
| 2016 Q2 | 2.54 Billion USD | 2.45% |
| 2016 Q3 | 2.6 Billion USD | 2.19% |
| 2016 FY | 2.89 Billion USD | 15.89% |
| 2016 Q4 | 2.89 Billion USD | 11.09% |
| 2015 Q3 | 2.43 Billion USD | 2.52% |
| 2015 Q2 | 2.37 Billion USD | 9.62% |
| 2015 Q1 | 2.16 Billion USD | -7.3% |
| 2015 Q4 | 2.49 Billion USD | 2.59% |
| 2015 FY | 2.49 Billion USD | 6.88% |
| 2014 Q2 | 2.11 Billion USD | -3.61% |
| 2014 Q4 | 2.33 Billion USD | -2.9% |
| 2014 Q1 | 2.19 Billion USD | -5.26% |
| 2014 FY | 2.33 Billion USD | 0.74% |
| 2014 Q3 | 2.4 Billion USD | 13.61% |
| 2013 Q4 | 2.31 Billion USD | -10.21% |
| 2013 Q1 | 2.39 Billion USD | -13.3% |
| 2013 FY | 2.31 Billion USD | -15.96% |
| 2013 Q2 | 2.58 Billion USD | 8.03% |
| 2013 Q3 | 2.58 Billion USD | -0.06% |
| 2012 Q1 | 2.34 Billion USD | 6.42% |
| 2012 Q3 | 2.71 Billion USD | 4.38% |
| 2012 Q4 | 2.75 Billion USD | 1.49% |
| 2012 FY | 2.75 Billion USD | 25.18% |
| 2012 Q2 | 2.6 Billion USD | 11.04% |
| 2011 FY | 2.2 Billion USD | 27.75% |
| 2011 Q4 | 2.2 Billion USD | 5.37% |
| 2011 Q3 | 2.09 Billion USD | 18.65% |
| 2011 Q2 | 1.76 Billion USD | 14.6% |
| 2011 Q1 | 1.53 Billion USD | -10.84% |
| 2010 Q3 | 1.88 Billion USD | 14.18% |
| 2010 Q2 | 1.65 Billion USD | -6.56% |
| 2010 Q1 | 1.77 Billion USD | -9.47% |
| 2010 Q4 | 1.72 Billion USD | -8.65% |
| 2010 FY | 1.72 Billion USD | -11.76% |
| 2009 FY | 1.95 Billion USD | 99.44% |
| 2009 Q1 | 1.56 Billion USD | 59.71% |
| 2009 Q2 | 1.43 Billion USD | -8.05% |
| 2009 Q3 | 1.57 Billion USD | 9.28% |
| 2009 Q4 | 1.95 Billion USD | 24.28% |
| 2008 Q3 | 1.06 Billion USD | 9.97% |
| 2008 Q4 | 980.47 Million USD | -8.16% |
| 2008 FY | 980.47 Million USD | 63.01% |
| 2008 Q1 | 889.5 Million USD | 47.89% |
| 2008 Q2 | 970.8 Million USD | 9.14% |
| 2007 Q3 | 655.14 Million USD | -13.92% |
| 2007 FY | 601.47 Million USD | -34.73% |
| 2007 Q2 | 761.07 Million USD | -8.86% |
| 2007 Q1 | 835.09 Million USD | -9.38% |
| 2007 Q4 | 601.47 Million USD | -8.19% |
| 2006 FY | 921.57 Million USD | 67.87% |
| 2006 Q4 | 921.57 Million USD | 2.16% |
| 2006 Q2 | 625.47 Million USD | 19.22% |
| 2006 Q1 | 524.65 Million USD | -4.43% |
| 2006 Q3 | 902.11 Million USD | 44.23% |
| 2005 Q4 | 548.99 Million USD | -0.29% |
| 2005 FY | 548.99 Million USD | 0.65% |
| 2005 Q1 | 484.22 Million USD | -11.22% |
| 2005 Q2 | 596.9 Million USD | 23.27% |
| 2005 Q3 | 550.57 Million USD | -7.76% |
| 2004 FY | 545.45 Million USD | -24.7% |
| 2004 Q2 | 624.05 Million USD | -6.75% |
| 2004 Q1 | 669.18 Million USD | -7.62% |
| 2004 Q3 | 574.36 Million USD | -7.96% |
| 2004 Q4 | 545.45 Million USD | -5.03% |
| 2003 Q1 | 840.3 Million USD | 3.01% |
| 2003 FY | 724.41 Million USD | -11.19% |
| 2003 Q2 | 787.45 Million USD | -6.29% |
| 2003 Q3 | 742.67 Million USD | -5.69% |
| 2003 Q4 | 724.41 Million USD | -2.46% |
| 2002 Q4 | 815.72 Million USD | -1.85% |
| 2002 FY | 815.72 Million USD | -11.83% |
| 2002 Q3 | 831.06 Million USD | -3.42% |
| 2002 Q2 | 860.47 Million USD | -1.72% |
| 2002 Q1 | 875.51 Million USD | -5.36% |
| 2001 Q4 | 925.13 Million USD | 0.3% |
| 2001 Q3 | 922.37 Million USD | 20.28% |
| 2001 Q2 | 766.83 Million USD | -0.35% |
| 2001 Q1 | 769.54 Million USD | -0.43% |
| 2001 FY | 925.13 Million USD | 19.7% |
| 2000 FY | 772.88 Million USD | 232.56% |
| 2000 Q1 | 396.93 Million USD | 70.8% |
| 2000 Q2 | 428.32 Million USD | 7.91% |
| 2000 Q3 | 774.56 Million USD | 80.84% |
| 2000 Q4 | 772.88 Million USD | -0.22% |
| 1999 Q2 | 238.6 Million USD | -4.45% |
| 1999 FY | 232.4 Million USD | -12.73% |
| 1999 Q4 | 232.4 Million USD | 3.38% |
| 1999 Q1 | 249.7 Million USD | -6.23% |
| 1999 Q3 | 224.8 Million USD | -5.78% |
| 1998 Q4 | 266.3 Million USD | -4.17% |
| 1998 FY | 266.3 Million USD | -9.91% |
| 1998 Q1 | 283.3 Million USD | -4.16% |
| 1998 Q2 | 274.9 Million USD | -2.97% |
| 1998 Q3 | 277.9 Million USD | 1.09% |
| 1997 Q2 | 300.7 Million USD | 3.83% |
| 1997 Q3 | 298.7 Million USD | -0.67% |
| 1997 Q1 | 289.6 Million USD | 101.81% |
| 1997 Q4 | 295.6 Million USD | -1.04% |
| 1997 FY | 295.6 Million USD | 105.99% |
| 1996 FY | 143.5 Million USD | 44.95% |
| 1996 Q4 | 143.5 Million USD | 0.0% |
| 1996 Q1 | 90.3 Million USD | -8.79% |
| 1996 Q2 | 73.7 Million USD | -18.38% |
| 1996 Q3 | 143.5 Million USD | 94.71% |
| 1995 Q4 | 99 Million USD | 0.71% |
| 1995 FY | 99 Million USD | -14.8% |
| 1995 Q1 | 111.8 Million USD | -3.79% |
| 1995 Q2 | 106.1 Million USD | -5.1% |
| 1995 Q3 | 98.3 Million USD | -7.35% |
| 1994 Q3 | 106.7 Million USD | -3.35% |
| 1994 Q2 | 110.4 Million USD | -3.07% |
| 1994 FY | 116.2 Million USD | 90.49% |
| 1994 Q1 | 113.9 Million USD | 86.72% |
| 1994 Q4 | 116.2 Million USD | 8.9% |
| 1993 FY | 61 Million USD | 19.61% |
| 1993 Q1 | 48.7 Million USD | -4.51% |
| 1993 Q2 | 51.6 Million USD | 5.95% |
| 1993 Q3 | 50.8 Million USD | -1.55% |
| 1993 Q4 | 61 Million USD | 20.08% |
| 1992 Q2 | 54.5 Million USD | -1.8% |
| 1992 Q1 | 55.5 Million USD | -2.8% |
| 1992 Q3 | 52.9 Million USD | -2.94% |
| 1992 Q4 | 51 Million USD | -3.59% |
| 1992 FY | 51 Million USD | -10.68% |
| 1991 Q3 | 32.4 Million USD | 343.84% |
| 1991 FY | 57.1 Million USD | 520.65% |
| 1991 Q2 | 7.3 Million USD | 0.0% |
| 1991 Q4 | 57.1 Million USD | 76.23% |
| 1990 FY | 9.2 Million USD | 0.0% |
| 1990 Q4 | 9.2 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Absci Corporation | 234.48 Million USD | -9593.876% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -3338.062% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -493.496% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -3598796.749% |
| Apollomics, Inc. | 55.38 Million USD | -40938.872% |
| 180 Life Sciences Corp. | 5.25 Million USD | -432076.133% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -23515.302% |
| Bicycle Therapeutics plc | 595.34 Million USD | -3717.994% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -10496.533% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -30740.683% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -30099.022% |
| Chimerix, Inc. | 212.77 Million USD | -10582.79% |
| CRISPR Therapeutics AG | 2.22 Billion USD | -919.488% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -17333.007% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -6299.556% |
| Fortress Biotech, Inc. | 167.52 Million USD | -13468.163% |
| Fortress Biotech, Inc. | 167.52 Million USD | -13468.163% |
| Gritstone bio, Inc. | 177.76 Million USD | -12686.369% |
| Allakos Inc. | 243.61 Million USD | -9230.569% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -17399.038% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -17962.204% |
| Cytokinetics, Incorporated | 824.31 Million USD | -2657.462% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -26038.985% |
| Innoviva, Inc. | 1.24 Billion USD | -1727.911% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -238655.633% |
| NLS Pharmaceutics AG | 1.84 Million USD | -1230794.364% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -13013.905% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -345001.657% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -8365.088% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -16036.961% |
| ImmuCell Corporation | 43.8 Million USD | -51785.836% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -3400.638% |
| Incyte Corporation | 6.78 Billion USD | -235.15% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -13043.066% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -736939.662% |
| Mustang Bio, Inc. | 17.74 Million USD | -128015.207% |
| MiMedx Group, Inc. | 239.04 Million USD | -9408.674% |
| MEI Pharma, Inc. | 41.37 Million USD | -54837.039% |
| MacroGenics, Inc. | 306.82 Million USD | -7308.318% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -309358.243% |
| Mereo BioPharma Group plc | 66.49 Million USD | -34081.266% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -132612.566% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -13199.67% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | -1428.132% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -39847.198% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -99677.007% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -715586.398% |
| NextCure, Inc. | 129.41 Million USD | -17463.399% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -23773.251% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -42033.536% |
| Onconetix, Inc. | 88.82 Million USD | -25490.891% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -61786.248% |
| Opthea Limited | 188.79 Million USD | -11939.861% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -15681.926% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -2007586.2% |
| PDS Biotechnology Corporation | 59.39 Million USD | -38172.722% |
| Precigen, Inc. | 151.04 Million USD | -14948.827% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -58664.736% |
| Prime Medicine, Inc. | 193.85 Million USD | -11625.604% |
| PureTech Health plc | 693.97 Million USD | -3175.372% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -3913.518% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 31.288% |
| Replimune Group, Inc. | 487.72 Million USD | -4560.483% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -186020.754% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -19290.232% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -439581.134% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | -988.303% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -120015.147% |
| Sesen Bio, Inc. | 189.17 Million USD | -11915.499% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -13649.214% |
| Solid Biosciences Inc. | 164.93 Million USD | -13680.974% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -3608.752% |
| SciSparc Ltd. | 11.18 Million USD | -203174.906% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -4728.651% |
| TG Therapeutics, Inc. | 329.58 Million USD | -6796.571% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -14616.199% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -281005.615% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -2781.205% |
| UroGen Pharma Ltd. | 178.31 Million USD | -12647.503% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -27756.661% |
| XOMA Corporation | 234.3 Million USD | -9601.282% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -3944.325% |
| AbCellera Biologics Inc. | 1.48 Billion USD | -1427.471% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -44735.395% |
| Cassava Sciences, Inc. | 151.66 Million USD | -14887.307% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -80297.156% |
| Precision BioSciences, Inc. | 159.78 Million USD | -14125.847% |
| Dyadic International, Inc. | 8.21 Million USD | -276448.818% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -131326.424% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -71513.737% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -23168.874% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -13230.323% |
| IGM Biosciences, Inc. | 423.41 Million USD | -5268.354% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -15335.63% |
| Acelyrin, Inc. | 742.69 Million USD | -2960.523% |
| Abeona Therapeutics Inc. | 64 Million USD | -35414.828% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -2628.506% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -156588.172% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -5193.455% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -13415.882% |
| Senti Biosciences, Inc. | 119.48 Million USD | -18923.635% |
| Mesoblast Limited | 669.15 Million USD | -3296.861% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -3847.867% |
| ChromaDex Corporation | 54.96 Million USD | -41254.705% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -386977.482% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -9304.186% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -284788.366% |
| Seer, Inc. | 436.26 Million USD | -5110.134% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -6569.699% |
| Novavax, Inc. | 1.85 Billion USD | -1125.122% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -235975.878% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -4390.209% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -422551.543% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -2930.576% |
| Celcuity Inc. | 191.21 Million USD | -11786.974% |
| ContextLogic Inc. | 423 Million USD | -5273.57% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -5392.483% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -13988.647% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | -99.504% |
| Amarin Corporation plc | 831.68 Million USD | -2633.033% |
| AnaptysBio, Inc. | 452.38 Million USD | -4924.481% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -91399.074% |
| Aptorum Group Limited | 20.64 Million USD | -110026.452% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -7351.303% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -2869.126% |
| Ardelyx, Inc. | 297.57 Million USD | -7538.375% |
| Celularity Inc. | 143.88 Million USD | -15697.038% |
| Omeros Corporation | 378.26 Million USD | -5909.004% |
| Humacyte, Inc. | 128.22 Million USD | -17627.085% |
| Immunocore Holdings plc | 597 Million USD | -3707.397% |
| IO Biotech, Inc. | 150.71 Million USD | -14981.278% |
| GT Biopharma, Inc. | 14.1 Million USD | -161004.26% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -8861.246% |
| Summit Therapeutics Inc. | 202.94 Million USD | -11099.957% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -274984.11% |
| Pulmatrix, Inc. | 33.95 Million USD | -66836.215% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -1647.164% |
| Evogene Ltd. | 51.1 Million USD | -44380.93% |
| CorMedix Inc. | 82.05 Million USD | -27599.503% |
| BioLineRx Ltd. | 63.92 Million USD | -35457.607% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -18282.247% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -23401.277% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | -1094.327% |
| scPharmaceuticals Inc. | 94.47 Million USD | -23958.468% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -8720.617% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -3557.213% |
| NLS Pharmaceutics AG | 1.84 Million USD | -1230794.364% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -120015.147% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -3817.17% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -20476.089% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -41458.855% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -9854.454% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -21056.968% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -70269.958% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -125864.272% |
| Daré Bioscience, Inc. | 21.28 Million USD | -106703.733% |
| bluebird bio, Inc. | 619.16 Million USD | -3571.129% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | -232.235% |
| DBV Technologies S.A. | 182.98 Million USD | -12321.825% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -3516.263% |
| Galecto, Inc. | 38.22 Million USD | -59361.114% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -30462.024% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -21767.316% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -7282.5% |
| GlycoMimetics, Inc. | 45.31 Million USD | -50058.8% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -6558.621% |
| ADMA Biologics, Inc. | 329.18 Million USD | -6805.056% |
| Clene Inc. | 52.34 Million USD | -43327.141% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -3377.166% |
| Aptose Biosciences Inc. | 12.92 Million USD | -175795.706% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -102685.15% |
| Soligenix, Inc. | 9.79 Million USD | -231904.12% |
| Century Therapeutics, Inc. | 360.69 Million USD | -6201.848% |
| Kura Oncology, Inc. | 448.93 Million USD | -4963.138% |
| Surrozen, Inc. | 46.08 Million USD | -49227.691% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -8252.116% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -20394.03% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -10979.741% |
| Autolus Therapeutics plc | 375.38 Million USD | -5955.235% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -8932.968% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -46163.535% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -5054.614% |
| GRI Bio, Inc. | 2.95 Million USD | -768851.286% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -214230.18% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -5875.232% |
| INmune Bio, Inc. | 57 Million USD | -39776.844% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -10115.545% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -26978.7% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -86932.674% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -194430.814% |
| Jaguar Health, Inc. | 50.76 Million USD | -44677.101% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -330127.46% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -30115.883% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -66718.155% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -13633.928% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -3510.238% |
| Verastem, Inc. | 149.71 Million USD | -15082.009% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -4338.157% |
| Histogen Inc. | 19.07 Million USD | -119074.75% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -100253.313% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -2934.918% |
| Surrozen, Inc. | 46.08 Million USD | -49227.691% |
| Organovo Holdings, Inc. | 6.34 Million USD | -357912.285% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -527451.745% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -266709.872% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -6162.298% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -125520.102% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -180130.769% |
| Kronos Bio, Inc. | 213.27 Million USD | -10557.496% |
| Turnstone Biologics Corp. | 112.81 Million USD | -20048.207% |
| Synaptogenix, Inc. | 31.11 Million USD | -72955.355% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -186457.781% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -4744.541% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -4047.377% |
| Exelixis, Inc. | 2.94 Billion USD | -672.517% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -6135.327% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -2781.873% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -23731.202% |
| ESSA Pharma Inc. | 149.12 Million USD | -15142.674% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -127152.583% |
| Avid Bioservices, Inc. | 336.55 Million USD | -6653.745% |
| Insmed Incorporated | 1.32 Billion USD | -1609.247% |
| MediWound Ltd. | 66.45 Million USD | -34101.839% |
| OmniAb, Inc. | 401.98 Million USD | -5554.49% |
| Alector, Inc. | 621.82 Million USD | -3555.39% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -6238.595% |
| Zai Lab Limited | 1.03 Billion USD | -2093.41% |
| AlloVir, Inc. | 190.79 Million USD | -11813.352% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -4650.76% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -8824.794% |
| Aura Biosciences, Inc. | 255.07 Million USD | -8811.183% |
| Immunic, Inc. | 54.29 Million USD | -41761.176% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -8437.998% |
| Veracyte, Inc. | 1.13 Billion USD | -1897.696% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -192157.626% |
| FibroGen, Inc. | 423.52 Million USD | -5266.858% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -646931.028% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -4716.669% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -479783.799% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -418544.297% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -258051.051% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -4292.7% |
| Fortrea Holdings Inc. | 4.35 Billion USD | -421.67% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -9555.826% |
| XBiotech Inc. | 227.24 Million USD | -9902.596% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -23731.202% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -6042.882% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -354892.972% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -15839.832% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -7849.957% |
| Agenus Inc. | 313.91 Million USD | -7140.923% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -17676.162% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -5850.33% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | -1424.48% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -6130.149% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -4296.897% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -122044.101% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -5938.024% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -212030.63% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -102514.174% |
| Lantern Pharma Inc. | 43.64 Million USD | -51976.613% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -17955.03% |
| Ainos, Inc. | 31.84 Million USD | -71284.775% |
| Pluri Inc. | 39.52 Million USD | -57405.503% |
| Prothena Corporation plc | 696.38 Million USD | -3164.042% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -7942.786% |
| Rallybio Corporation | 115.62 Million USD | -19559.401% |
| Kodiak Sciences Inc. | 479.37 Million USD | -4641.662% |
| Cue Biopharma, Inc. | 61.53 Million USD | -36841.654% |
| MeiraGTx Holdings plc | 458.16 Million USD | -4861.106% |
| Annexon, Inc. | 297.67 Million USD | -7535.937% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -16434.782% |
| Moderna, Inc. | 18.42 Billion USD | -23.359% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -72615.698% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -33068.247% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -2066.328% |
| Immix Biopharma, Inc. | 19.92 Million USD | -113977.879% |
| CalciMedica, Inc. | 12.18 Million USD | -186442.47% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -7383.07% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -7207.924% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -8167.06% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -3920.916% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -83633.147% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -17359.382% |
| Nutriband Inc. | 7.51 Million USD | -302277.735% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -28689.168% |
| Vor Biopharma Inc. | 209.82 Million USD | -10732.777% |
| Roivant Sciences Ltd. | 7.22 Billion USD | -214.715% |
| Alkermes plc | 2.13 Billion USD | -964.037% |
| ProKidney Corp. | 420.55 Million USD | -5304.849% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -41353.504% |
| Arcellx, Inc. | 825.13 Million USD | -2654.735% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -4060.145% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -5546.315% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -80503.546% |
| Atai Life Sciences N.V. | 293.47 Million USD | -7645.112% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -13833.842% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -17739.081% |
| MediciNova, Inc. | 66.26 Million USD | -34199.393% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -25745.045% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -509275.634% |
| GeoVax Labs, Inc. | 9.28 Million USD | -244752.567% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -3764.129% |
| Biomea Fusion, Inc. | 199.92 Million USD | -11269.25% |
| RenovoRx, Inc. | 1.46 Million USD | -1550391.132% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -4585.712% |
| Geron Corporation | 394.07 Million USD | -5667.974% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -310634.108% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -6587.497% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -13669.036% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -4218.687% |
| Royalty Pharma plc | 16.38 Billion USD | -38.752% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -8085.37% |
| Imunon, Inc. | 21.91 Million USD | -103605.304% |
| BioAtla, Inc. | 119.65 Million USD | -18895.972% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -3435.92% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -23593.334% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -9954.941% |
| Structure Therapeutics Inc. | 482.01 Million USD | -4615.642% |
| 89bio, Inc. | 596.26 Million USD | -3712.071% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -10174.233% |
| aTyr Pharma, Inc. | 122.06 Million USD | -18521.085% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -14669.173% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -4534.806% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -149859.502% |
| Akari Therapeutics, Plc | 4.35 Million USD | -521833.41% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -133314.074% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -1211.406% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -9807.292% |
| Liquidia Corporation | 120.43 Million USD | -18774.044% |
| Entera Bio Ltd. | 11.76 Million USD | -193101.87% |
| GH Research PLC | 226.3 Million USD | -9944.278% |
| Vericel Corporation | 353.65 Million USD | -6327.188% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -15641.027% |
| Xencor, Inc. | 952.69 Million USD | -2285.892% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -291920.41% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -86932.674% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -281524.946% |
| Vaxcyte, Inc. | 1.4 Billion USD | -1514.456% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -2255.954% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -3405.367% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -736939.662% |
| Portage Biotech Inc. | 7.77 Million USD | -292099.512% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -509275.634% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -8107.478% |
| OncoCyte Corporation | 74.89 Million USD | -30250.638% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -1117825.605% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -392704.602% |
| Purple Biotech Ltd. | 44.3 Million USD | -51207.39% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -43948.214% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -50091.446% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -6731.117% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -66506.693% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -59376.673% |
| United Therapeutics Corporation | 7.16 Billion USD | -217.151% |
| HilleVax, Inc. | 344.43 Million USD | -6499.29% |
| Silo Pharma, Inc. | 7.74 Million USD | -293339.017% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -476047.982% |
| Pharming Group N.V. | 462.85 Million USD | -4810.879% |
| Tharimmune, Inc. | 10.94 Million USD | -207550.136% |
| Genprex, Inc. | 10.67 Million USD | -212917.235% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -5562.674% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -4480.901% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -12983.937% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -936841.467% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -545585.319% |
| OKYO Pharma Limited | 1.54 Million USD | -1474676.547% |
| Savara Inc. | 177.56 Million USD | -12701.131% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -70041.949% |
| Curis, Inc. | 77.28 Million USD | -29312.023% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -35444.371% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -117241.387% |
| BeiGene, Ltd. | 5.8 Billion USD | -291.544% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -6250.087% |
| Erasca, Inc. | 395.29 Million USD | -5650.157% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -525652.023% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -525652.023% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -124674.661% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -196086.777% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -16339.591% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -4781.633% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -7151.92% |
| Adicet Bio, Inc. | 207.29 Million USD | -10865.146% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -2822.07% |
| Aditxt, Inc. | 44.57 Million USD | -50889.352% |
| Adagene Inc. | 115.72 Million USD | -19540.913% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -510210.631% |
| Quantum-Si incorporated | 298.25 Million USD | -7521.19% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -294748.065% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -6370.66% |
| Compugen Ltd. | 121.33 Million USD | -18633.578% |
| Generation Bio Co. | 374.75 Million USD | -5965.301% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -8825.495% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -14234.761% |
| Invivyd, Inc. | 229.18 Million USD | -9818.012% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -2593.215% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -186683.119% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -12362.416% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -111191.618% |
| 2seventy bio, Inc. | 565.42 Million USD | -3920.013% |
| Instil Bio, Inc. | 325.63 Million USD | -6880.377% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -38600.026% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -437868.384% |
| GeoVax Labs, Inc. | 9.28 Million USD | -244752.567% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -21837.986% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -23200.589% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -9271.23% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | -1059.651% |
| Evaxion Biotech A/S | 12.88 Million USD | -176258.693% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -8917.774% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -2919.87% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -9963.979% |
| Cingulate Inc. | 3.49 Million USD | -650927.256% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -136590.12% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -34502.223% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -17955.317% |
| Clearmind Medicine Inc. | 4.32 Million USD | -525528.014% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -14125.58% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -265420.798% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -6068.471% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -3448.561% |
| ImmunityBio, Inc. | 504.45 Million USD | -4405.919% |
| Korro Bio, Inc. | 221.66 Million USD | -10154.395% |
| Kineta, Inc. | 10.28 Million USD | -220989.388% |
| BioVie Inc. | 25.2 Million USD | -90069.347% |
| Codexis, Inc. | 136.56 Million USD | -16544.723% |
| Celularity Inc. | 143.88 Million USD | -15697.038% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -18955.212% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -3477.57% |
| Virax Biolabs Group Limited | 5.48 Million USD | -414384.473% |
| Cibus, Inc. | 544.41 Million USD | -4075.191% |
| IN8bio, Inc. | 33.7 Million USD | -67330.657% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -13038.085% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -108175.139% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -660.189% |
| Eyenovia, Inc. | 28.77 Million USD | -78880.87% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -9760.06% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -314548.394% |
| Elevation Oncology, Inc. | 89.09 Million USD | -25413.464% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -37207.882% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -27743.012% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -4817.03% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -73819.35% |
| Moolec Science SA | 24.05 Million USD | -94407.201% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -7229.367% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -22248.048% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -3720.407% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -14389.371% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -324857.844% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -188888.133% |
| Humacyte, Inc. | 128.22 Million USD | -17627.085% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -8914.483% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -1228559.459% |
| Genelux Corporation | 27.89 Million USD | -81390.697% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -25324.426% |
| Notable Labs, Ltd. | 19.54 Million USD | -116220.557% |
| Immunovant, Inc. | 666.71 Million USD | -3309.298% |
| Quantum-Si incorporated | 298.25 Million USD | -7521.19% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -41868.612% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -12848.287% |
| Acasti Pharma Inc. | 73.3 Million USD | -30909.823% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -499214.519% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -12479.597% |
| PepGen Inc. | 143.05 Million USD | -15789.467% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -118379.02% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -386977.482% |
| Immuneering Corporation | 102.58 Million USD | -22057.53% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -527451.745% |
| Belite Bio, Inc | 94.64 Million USD | -23917.033% |
| XOMA Corporation | 234.3 Million USD | -9601.282% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -9647.586% |
| Bionomics Limited | 27.64 Million USD | -82109.568% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -21066.425% |
| uniQure N.V. | 831.68 Million USD | -2633.017% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -510210.631% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -8199.177% |
| Forte Biosciences, Inc. | 38.98 Million USD | -58212.468% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -557954.599% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -61614.86% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -314548.394% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -646931.028% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -192186.609% |
| Altimmune, Inc. | 210.64 Million USD | -10691.018% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -11961.277% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -21066.425% |
| Peak Bio, Inc. | 2.59 Million USD | -875345.566% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -13090.156% |
| Benitec Biopharma Inc. | 52.21 Million USD | -43436.104% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -6548.999% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -65267.383% |
| Zura Bio Limited | 100.84 Million USD | -22440.186% |
| PolyPid Ltd. | 15.37 Million USD | -147767.551% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -65267.383% |
| argenx SE | 4.54 Billion USD | -400.394% |
| Immunome, Inc. | 148.54 Million USD | -15202.41% |
| Verona Pharma plc | 308.12 Million USD | -7276.965% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -26038.985% |
| Shattuck Labs, Inc. | 159.56 Million USD | -14145.193% |
| CervoMed Inc. | 9.97 Million USD | -227828.324% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -199497.822% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -12569.77% |
| Moolec Science SA | 24.05 Million USD | -94407.201% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -371461.493% |
| Design Therapeutics, Inc. | 289.64 Million USD | -7747.661% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -31112.084% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -419431.192% |
| Achilles Therapeutics plc | 161.45 Million USD | -13978.263% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -265420.798% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -11304.96% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -29724.962% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -39146.84% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -4216.898% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -10708.721% |
| Beam Therapeutics Inc. | 1.45 Billion USD | -1457.168% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -3415.228% |
| AEON Biopharma, Inc. | 6.84 Million USD | -331970.124% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -17064.843% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -8260.779% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -165670.241% |
| NeurAxis, Inc. | 509.49 Thousand USD | -4461193.273% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -2812.817% |
| Lumos Pharma, Inc. | 40.63 Million USD | -55833.363% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -32174.472% |
| Palisade Bio, Inc. | 14.05 Million USD | -161657.757% |
| Nutriband Inc. | 7.51 Million USD | -302277.735% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -8413.375% |
| Neurogene Inc. | 222.57 Million USD | -10112.47% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -366397.904% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -4917.305% |
| Athira Pharma, Inc. | 160.24 Million USD | -14084.655% |
| HCW Biologics Inc. | 28.51 Million USD | -79616.88% |
| XOMA Corporation | 234.3 Million USD | -9601.282% |
| Nektar Therapeutics | 398.03 Million USD | -5610.632% |
| Arvinas, Inc. | 1.3 Billion USD | -1642.312% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -133314.074% |
| Merus N.V. | 458.49 Million USD | -4857.579% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -11022.3% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -12513.593% |
| Rezolute, Inc. | 132.73 Million USD | -17024.238% |
| Clene Inc. | 52.34 Million USD | -43327.141% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -152207.597% |
| BeyondSpring Inc. | 24.8 Million USD | -91524.476% |
| Synlogic, Inc. | 75.55 Million USD | -29986.3% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -191521.986% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -242640.282% |
| Peak Bio, Inc. | 2.59 Million USD | -875345.566% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -12901.092% |
| Krystal Biotech, Inc. | 818.35 Million USD | -2677.548% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -9353.664% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -3031.796% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -635323.382% |
| MannKind Corporation | 475.19 Million USD | -4683.311% |
| Ikena Oncology, Inc. | 192.09 Million USD | -11732.976% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -169858.128% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -19404.372% |
| Gossamer Bio, Inc. | 311.91 Million USD | -7187.282% |
| CohBar, Inc. | 16.36 Million USD | -138789.542% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -64542.38% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -310634.108% |
| Legend Biotech Corporation | 1.84 Billion USD | -1129.584% |
| Mural Oncology plc | 301.74 Million USD | -7432.917% |
| Disc Medicine, Inc. | 367.99 Million USD | -6076.752% |
| Champions Oncology, Inc. | 26.13 Million USD | -86882.244% |
| REGENXBIO Inc. | 573.97 Million USD | -3860.172% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -839245.885% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -14622.967% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -188132.781% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -6584.665% |
| Vaxart, Inc. | 91.83 Million USD | -24652.477% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -37844.452% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -15224.394% |
| Cellectis S.A. | 334.27 Million USD | -6699.952% |
| Longeveron Inc. | 12.17 Million USD | -186549.696% |
| Repare Therapeutics Inc. | 253.9 Million USD | -8852.387% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -596.268% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -11217.172% |
| Revolution Medicines, Inc. | 2.08 Billion USD | -988.303% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -1398681.538% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -8084.84% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -13836.529% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -16282.835% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -88961.202% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -1869.83% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -186020.754% |
| Veru Inc. | 50.59 Million USD | -44824.962% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -49798.36% |
| Cingulate Inc. | 3.49 Million USD | -650927.256% |
| Passage Bio, Inc. | 150.54 Million USD | -14998.608% |
| Context Therapeutics Inc. | 16.06 Million USD | -141408.902% |
| Exicure, Inc. | 11.58 Million USD | -196188.428% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -5944.494% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -13962.063% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -129995.009% |
| Nuvalent, Inc. | 732.38 Million USD | -3003.59% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -152001.712% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -25281.557% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -160073.349% |
| OmniAb, Inc. | 401.98 Million USD | -5554.49% |
| Anew Medical, Inc. | 19.45 Million USD | -116729.024% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -84947.25% |
| Lipocine Inc. | 23 Million USD | -98722.351% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -16158.27% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -7338.745% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -26978.7% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -18601.827% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -286354.946% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -2476.311% |
| Ocugen, Inc. | 64.54 Million USD | -35114.96% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -18151.178% |
| Q32 Bio Inc. | 306.11 Million USD | -7325.282% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -540066.35% |
| Alumis Inc. Common Stock | 89.61 Million USD | -25265.13% |
| Equillium, Inc. | 50.53 Million USD | -44883.574% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -30128.34% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -54972.109% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -1336300.03% |
| Dominari Holdings Inc. | 57.55 Million USD | -39390.948% |
| Edesa Biotech, Inc. | 8.89 Million USD | -255570.222% |
| vTv Therapeutics Inc. | 11.01 Million USD | -206200.599% |
| Bio-Techne Corporation | 2.81 Billion USD | -707.987% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -2325.543% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -2701.19% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -8086.196% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -54406.259% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -3304.825% |
| Nkarta, Inc. | 378.88 Million USD | -5899.235% |
| BioCardia, Inc. | 2.98 Million USD | -760870.874% |
| Iterum Therapeutics plc | 26.25 Million USD | -86461.56% |